Defining high, medium and low impact prognostic factors for developing multiple sclerosis.
about
Current status of biomarker research in neurologyNewer therapies for multiple sclerosisAlemtuzumab in the treatment of multiple sclerosis: patient selection and special considerationsTreatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.A practical review of the neuropathology and neuroimaging of multiple sclerosis.Outcome Measures in Clinical Trials for Multiple Sclerosis.The impact of multiple sclerosis onset symptom on cardiac repolarizationLong Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational StudyMRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.Neurofilament light chain level is a weak risk factor for the development of MS.Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life settingMcDonald Criteria 2010 and 2005 Compared: Persistence of High Oligoclonal Band Prevalence Despite Almost Doubled Diagnostic SensitivityImportance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients.Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis-The PaSiMS II study.Multiple sclerosis in 2015: Managing the complexity of multiple sclerosis.Prognostic indicators in pediatric clinically isolated syndrome.Multiple sclerosis: assay of free immunoglobulin light chains.Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes.Multiple sclerosis: integration of modeling with biology, clinical and imaging measures to provide better monitoring of disease progression and prediction of outcome.Personalised medicine for multiple sclerosis care.Treatment decisions in multiple sclerosis - insights from real-world observational studies.Disease course after clinically isolated syndrome in children versus adults: a prospective cohort study.Imaging Markers for Monitoring Disease Activity in Multiple Sclerosis.Modeling the course and outcomes of MS is statistical twaddle--No.Cytotoxic CD4+ T Cells Drive Multiple Sclerosis Progression.The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.A supervised framework with intensity subtraction and deformation field features for the detection of new T2-w lesions in multiple sclerosis.SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.Clinically Isolated Syndrome According to McDonald 2010: Intrathecal IgG Synthesis Still Predictive for Conversion to Multiple Sclerosis.Definition, prevalence and predictive factors of benign multiple sclerosis.Lesion topographies in multiple sclerosis diagnosis: A reappraisal.Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?Low clinical conversion rate in clinically isolated syndrome patients - diagnostic benefit of McDonald 2010 criteria?Decreased Neuro-Axonal Proteins in CSF at First Attack of Suspected Multiple Sclerosis.Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study.MRI for multiple sclerosis diagnosis and prognosis.Progression of regional atrophy in the left hemisphere contributes to clinical and cognitive deterioration in multiple sclerosis: A 5-year study.Improved Automatic Detection of New T2 Lesions in Multiple Sclerosis Using Deformation Fields.Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor.
P2860
Q26744505-0079FE9E-BBD3-45F1-A9F2-6C48DAF2A8CAQ26779900-2EB8A27E-DCC1-428A-964F-11D772AF6116Q28077000-AD2E92EB-848A-4886-B858-E7519ED7786EQ30234672-89688F0F-C6B7-494D-96FA-B83731D986DDQ31062386-B01E125A-06A5-4194-BA54-94A3F1FC711EQ31160866-6148AFFA-9681-4F84-8175-51C5A21232C2Q33917429-C753F401-C6C4-4EB8-B09A-2AEA70010DE3Q36071620-EC293FE8-4EE6-4A2F-BCBD-8CAA6E4D2239Q36599053-E14FD8DD-00EC-40D6-AE71-6D6744AAE5E4Q37265143-A70964D7-3EE7-4976-87E8-116236D44C8FQ37282063-583CD5F9-309E-49C5-8FE0-FEE6C429CFC9Q37286668-4E9A42EE-CB8B-457D-9279-2ACF861F99A9Q37416267-9CD3D15B-AA89-4201-901B-3748053E1872Q38654791-F400DA1F-57BF-4C17-A7C4-6A6D6365810BQ38657539-73EE98F6-1BE1-4FDC-AEB1-D8B8BA5EACF2Q38715565-8AE0DC4D-B447-4442-8C6C-CA3D7CF192EAQ38821503-CF0F2153-1D56-4000-A6B3-6A5E45242428Q38832474-1EBF6522-D274-40F1-8577-420F72D739D5Q38845037-02BBC53A-043F-4A68-8936-2F2D89AEAA30Q38961503-1E4A1282-CE88-4AE4-B457-B8354C9573D8Q38965403-4F66256D-9C06-476E-939D-06C9BD634B71Q39022643-C5D8AE30-EFD1-4D8B-8CEA-801D3A04C44DQ39174716-DBBC0DE6-46F5-44E3-A082-8B41AC09FA23Q39247449-42D82594-D4F1-4341-80E2-C130DE24339EQ40938712-4FE673C0-1320-4C82-BB89-D462E768FD36Q42363220-50F66BC3-2274-42F0-8C00-F06DCD3804DAQ45066717-246BC788-9B75-415A-8211-58771F89ACF5Q45943006-7B683F95-E8E8-4A14-AE7A-BC50AB7DB400Q46861116-EBCE9AE5-FA73-44D2-ACC3-C41A4F457283Q47105069-B7080EA8-D93A-40E5-AC9F-7F5E504409BFQ47116223-01AE7419-3308-42E9-BAEB-DAA1F019726FQ47138738-3884D376-25DA-49B5-9893-024C5AF527F5Q47186219-7B7CAB8C-8038-475F-A055-4D3318AE9DACQ47245418-7AD083E8-56B7-45E3-914E-AC0BDAC5A6B8Q47755754-B35ED118-8041-4CEA-9457-DFE4BAD689B8Q47868081-80693369-64B3-43F3-A8E1-EE888928F1DAQ47967192-E082B2C4-EF76-4635-A576-16C79AED9407Q48160589-8E89AAE9-7AA4-4718-BBFC-B5FB74E1C8A2Q48206411-14CAA33C-61B5-4CDA-BEA2-1A7420C38640Q48260470-BDBC6063-1592-488F-8B19-E678F932CE9D
P2860
Defining high, medium and low impact prognostic factors for developing multiple sclerosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Defining high, medium and low ...... developing multiple sclerosis.
@en
type
label
Defining high, medium and low ...... developing multiple sclerosis.
@en
prefLabel
Defining high, medium and low ...... developing multiple sclerosis.
@en
P2093
P50
P356
P1433
P1476
Defining high, medium and low ...... developing multiple sclerosis.
@en
P2093
Carlos Nos
Cristina Auger
Joaquin Castilló
Manuel Comabella
Raquel Mitjana
Susana Otero-Romero
Àlex Rovira
P304
P356
10.1093/BRAIN/AWV105
P407
P50
P577
2015-04-21T00:00:00Z